Metelimumab

From Self-sufficiency
Jump to: navigation, search
Metelimumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target TGF beta 1
Identifiers
CAS Number 272780-74-2
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future[1], Metelimumab was dropped from further development in favour of GC-1008[2], which is currently being developed by Genzyme[3].

History

CAT-192 was isolated by Cambridge Antibody Technology using its phage display technology. In 2000, Cambridge Antibody Technology signed a collaborative deal with Genzyme to further develop TGF beta antibodies[4][5].

In 2004, Cambridge Antibody Technology and Genzyme revealed that Phase I/II trials of CAT-192 for scleroderma showed the human anti-TGF-Beta1 monoclonal antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]

Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of GC-1008[2], which is currently being developed by Genzyme[3].

References

  1. ↑ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
  2. ↑ 2.0 2.1 http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
  3. ↑ 3.0 3.1 http://www.genzymeoncology.com/onc/research/onc_p_research.asp
  4. ↑ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
  5. ↑ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
  6. ↑ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
  7. ↑ http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
"-limu-" (immune system)
"-kinu-" (interleukin as target)
"-tumu-"/"-tu-" (tumor)
"-osu-" (bone)
"-mulu-" (musculoskeletal)
"-fungu-" (fungal)
"-viru-" (viral)
"-bacu-" (bacterial)
"-ciru-" (cardiovascular)
"-neru-" (neurologic)


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Metelimumab&oldid=23061"